The FDA on January 17, 2012 approved VORAXAZE® for the treatment of toxic plasma methotrexate concentrations (> 1 μmol/L) in patients with delayed methotrexate clearance due to impaired renal function. VORAXAZE® is a product of BTG International Inc.
The FDA on January 30, 2012 approved ERIVEDGE® for the treatment of adults with metastatic basal cell carcinoma or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. ERIVEDGE® is a product of Genentech, Inc.
The FDA on January 31, 2012 granted regular approval for GLEEVEC® (Imatinib mesylate) for the adjuvant treatment of adult patients for a period of 36 months following complete gross resection of Kit (CD117) positive Gastrointestinal Stromal Tumors (GIST). GLEEVEC® is a product of Novartis Pharmaceuticals.
The FDA on April 26, 2012 approved VOTRIENT® for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The efficacy of pazopanib for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors (GIST) has not been demonstrated. VOTRIENT® is a product of GlaxoSmithKline.
The FDA on June 8, 2012 approved PERJETA® injection for use in combination with HERCEPTIN® (Trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. PERJETA® is a product of Genentech, Inc.
The FDA on July 9, 2012 granted approval to ERBITUX® for use in combination with FOLFIRI (CAMPTOSAR® [Irinotecan], 5-fluorouracil, leucovorin) for first-line treatment of patients with K-ras mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use. ERBITUX® is a product of Eli Lilly and Co.
The FDA on July 20, 2012 granted accelerated approval to KYPROLIS® for the treatment of patients with multiple myeloma who have received at least two prior therapies, including VELCADE® (Bortezomib) and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. KYPROLIS® is a product of Onyx Pharmaceuticals.
The FDA on July 20, 2012 approved AFINITOR® for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with FEMARA® (Letrozole) or ARIMIDEX® (Anastrozole). AFINITOR® is a product of Novartis Pharmaceuticals Corporation.